mosquitoborn
chikungunya
viru
chikv
becom
major
global
health
problem
upon
infect
chikungunya
fever
chikf
result
longterm
joint
pain
arthriti
despit
intens
research
licens
vaccin
chikv
avail
develop
two
recombin
chimpanze
adenovirusvector
vaccin
induc
swift
robust
antichikv
immun
respons
singl
dose
without
need
adjuv
booster
vaccin
report
vaccin
protect
efficaci
chikv
infect
lethal
mous
model
result
indic
singl
unadjuv
chik
chik
dose
provid
complet
protect
lethal
viru
challeng
prevent
chikvassoci
sever
inflamm
candid
vaccin
support
surviv
equal
attenu
chikv
refer
vaccin
without
vaccinerel
side
effect
weight
loss
vaccin
either
chik
chik
result
high
titer
neutral
antibodi
associ
protect
indic
presenc
capsid
within
vaccin
construct
may
essenti
afford
protect
condit
test
conclud
replicationdefici
chik
vaccin
safe
even
use
mice
afford
complet
protect
lethal
challeng
chikungunya
viru
chikv
etiolog
agent
chikungunya
fever
chikf
acut
febril
ill
result
longterm
arthralgia
mainli
distal
joint
extrem
sever
largescal
outbreak
result
million
infect
worldwid
unlik
mani
arbovirus
clinic
import
percentag
chikv
infect
result
symptomat
diseas
high
chronic
phase
ill
last
year
comorbid
exacerb
diseas
review
furthermor
swell
arthriti
peripher
joint
hand
feet
result
debilit
diseas
directli
affect
patient
qualiti
life
place
burden
local
caretak
commun
present
licens
treatment
chikf
despit
effort
made
year
licens
vaccin
chikv
yet
avail
review
adenovirus
use
viral
vector
decad
recent
novel
adenovirus
priorit
mainli
due
preexist
adenoviru
immun
common
serotyp
eg
target
human
popul
simian
adenovirus
develop
follow
concern
preexist
immun
human
adenovir
serotyp
could
limit
use
vaccin
inde
simian
adenovirus
minim
seropreval
human
first
report
use
chimpanze
adenoviru
viralvector
vaccin
made
xiang
et
al
demonstr
induct
immun
respons
rabi
glycoprotein
express
chimpanze
adenoviru
serotyp
novel
vaccin
vector
recent
deriv
chimpanze
adenoviru
isol
subgroup
e
viral
vector
known
engin
univers
oxford
replicationincompet
viru
delet
region
recombin
vector
success
use
vaccin
wide
varieti
pathogen
furthermor
phase
clinic
trial
chadox
viral
vector
diseas
influenza
tuberculosi
mer
hiv
malaria
meningitidi
b
demonstr
safeti
immunogen
develop
two
vaccin
induc
swift
robust
antichikv
immun
respons
upon
singl
dose
without
need
adjuv
booster
dose
chik
formerli
known
schikv
encod
cassett
express
chikv
structur
protein
capsid
chik
formerli
known
schikv
express
structur
protein
capsid
manuscript
report
abil
replicationdefici
chimpanze
adenovirusvector
vaccin
chik
chik
induc
immun
afford
protect
highli
suscept
lethal
mous
model
vaccin
fulli
protect
lethal
chikv
challeng
viremia
weight
loss
data
highlight
use
chimpanze
adenoviru
vector
platform
chikv
vaccin
order
test
efficaci
vaccin
prevent
chikvinduc
diseas
mous
model
use
mice
chosen
sever
reason
includ
abil
determin
whether
vaccin
safe
wellcharacter
predict
cours
diseas
high
suscept
lethal
chikv
infect
absenc
neutral
antibodi
clear
correl
protect
ie
reduct
viremia
decreas
foot
swell
weight
loss
need
determin
efficaci
vaccin
test
studi
includ
chik
chik
refer
attenu
vaccin
use
posit
control
neg
control
includ
offtarget
vaccin
zika
known
prme
sham
vaccin
pb
mice
toler
intramuscular
inocul
vaccin
evidenc
absenc
weight
loss
day
follow
vaccin
figur
sudden
weight
loss
day
post
pb
inject
group
correspond
fight
observ
cage
resolut
separ
correl
weight
recoveri
mice
signific
weight
loss
observ
mice
vaccin
mice
demonstr
sign
diseas
includ
ruffl
coat
weight
loss
day
post
vaccin
mice
continu
recov
date
challeng
comparison
weight
loss
pb
mice
signific
day
post
vaccin
figur
vaccin
result
weight
loss
occur
vaccin
percentag
weight
chang
follow
vaccin
shown
weight
mice
group
compar
weight
vaccin
day
data
repres
mean
sem
twoway
repeat
measur
anova
dunnett
compar
pb
group
p
p
neutral
antibodi
key
correl
protect
alphaviru
vaccin
therefor
plaqu
reduct
neutral
test
prnt
cutoff
import
paramet
vaccin
efficaci
mice
vaccin
chik
chik
measur
supplementari
figur
titer
post
vaccin
figur
expect
mice
inocul
pb
zika
neutral
antibodi
chikv
la
reunion
strain
chikvlr
statist
signific
differ
titer
elicit
chik
chik
compar
either
pb
zika
oneway
anova
multipl
comparison
p
neutral
antibodi
key
correl
protect
alphaviru
vaccin
therefor
plaqu
reduct
neutral
test
prnt
cutoff
import
paramet
vaccin
efficaci
mice
vaccin
chik
chik
measur
prnt
supplementari
figur
prnt
titer
post
vaccin
figur
expect
mice
inocul
pb
zika
neutral
antibodi
chikv
la
reunion
strain
chikvlr
statist
signific
differ
prnt
titer
elicit
chik
chik
compar
either
pb
zika
oneway
anova
multipl
comparison
p
neutral
antibodi
key
correl
protect
alphaviru
vaccin
therefor
plaqu
reduct
neutral
test
prnt
cutoff
import
paramet
vaccin
efficaci
mice
vaccin
chik
chik
measur
supplementari
figur
titer
post
vaccin
figur
expect
mice
inocul
pb
zika
neutral
antibodi
chikv
la
reunion
strain
chikvlr
statist
signific
differ
titer
elicit
chik
chik
compar
either
pb
zika
oneway
anova
multipl
comparison
p
one
month
vaccin
mice
challeng
lethal
dose
chikvlr
backtit
pfumous
left
rear
foot
weight
loss
foot
swell
associ
chikvcaus
diseas
mice
paramet
measur
daili
consecut
day
percentag
initi
weight
prior
challeng
shown
figur
mice
pbstreat
zikavaccin
group
lost
weight
challeng
correl
low
neutral
protect
antibodi
prnt
limit
assay
detect
mice
vaccin
chik
chik
fulli
protect
weight
loss
importantli
even
lowest
weight
record
mous
along
whole
post
challeng
period
significantli
higher
chik
chik
group
compar
pb
figur
detect
lod
assay
valu
record
neutral
valu
lod
dot
repres
titer
anim
bar
repres
mean
sem
oneway
anova
sidak
multipl
comparison
test
p
p
one
month
vaccin
mice
challeng
lethal
dose
chikvlr
backtit
pfumous
left
rear
foot
weight
loss
foot
swell
associ
chikvcaus
diseas
mice
paramet
measur
daili
consecut
day
percentag
initi
weight
prior
challeng
shown
figur
mice
pbstreat
zikavaccin
group
lost
weight
challeng
correl
low
neutral
protect
antibodi
prnt
limit
assay
detect
mice
vaccin
chik
chik
fulli
protect
weight
loss
importantli
even
lowest
weight
record
mous
along
whole
post
challeng
period
significantli
higher
chik
chik
group
compar
pb
figur
one
advantag
mous
model
studi
chikv
infect
abil
measur
surviv
follow
challeng
addit
protect
weight
loss
mice
vaccin
chik
chik
vaccin
surviv
challeng
chikvlr
tabl
group
significantli
differ
pb
group
fail
protect
mice
result
morbid
trigger
euthanasia
day
postchalleng
offtarget
zikavaccin
mice
show
statist
signific
differ
pbstreat
mice
tabl
swell
hallmark
chikv
infect
inject
foot
mice
surviv
infect
also
fulli
protect
swell
inject
site
convers
mice
weight
loss
lethal
diseas
signific
swell
start
day
post
challeng
fail
resolv
swell
seen
chikv
infect
left
rear
foot
contralater
right
rear
control
foot
figur
swell
rapidli
increas
pb
zika
group
peak
day
post
infect
fail
resolv
anim
reach
human
endpoint
euthan
figur
signific
swell
seen
chik
chik
mice
either
foot
figur
b
previou
studi
shown
viremia
mice
occur
day
therefor
determin
vaccin
could
protect
viremia
blood
taken
mice
day
post
challeng
correspond
predict
day
peak
viremia
consist
surviv
foot
swell
mice
pbstreat
zikavaccin
viremia
approxim
pfuml
figur
none
vaccin
mice
detect
viremia
previou
studi
shown
viremia
mice
occur
day
therefor
determin
vaccin
could
protect
viremia
blood
taken
mice
day
post
challeng
correspond
predict
day
peak
viremia
consist
surviv
foot
swell
mice
pbstreat
zikavaccin
viremia
approxim
log
pfuml
figur
none
vaccin
mice
detect
viremia
adenovirus
use
viral
vector
decad
review
human
adenovirus
develop
chikv
viralvector
vaccin
shown
induc
robust
immun
respons
mice
vaccin
test
mice
adenovirus
use
viral
vector
decad
review
human
adenovirus
develop
chikv
viralvector
vaccin
shown
induc
robust
immun
respons
mice
vaccin
test
mice
produc
high
level
neutral
antibodi
chikv
foot
infect
chikv
mous
strain
lethal
vaccin
efficaci
measur
includ
absenc
viremia
protect
swell
present
result
similar
previou
studi
chik
chik
vaccin
trigger
protect
immun
respons
main
correl
protect
chikvcaus
diseas
like
neutral
antibodi
base
varieti
studi
vaccin
mice
studi
measur
prnt
titer
neutral
antibodi
one
necessari
neutral
chikv
albeit
lower
level
expect
could
due
mous
strain
versu
level
immunocompet
type
interferon
compet
versu
defici
andor
mous
age
mous
model
sensit
model
chikvcaus
diseas
therefor
lack
interferon
type
respons
may
neg
influenc
product
neutral
antibodi
moreov
pair
vaccin
appropri
adjuv
may
improv
product
neutral
antibodi
immun
chikv
human
adenoviru
vector
vaccin
work
well
mice
preexist
immun
adenovirus
howev
due
high
seropreval
popular
human
adenovirus
popul
primat
adenovirus
lower
human
seropreval
like
gorilla
chimpanze
one
pursu
primat
adenovirus
shown
other
effect
vector
platform
strain
mous
chosen
vaccin
studi
chikv
diseas
critic
sinc
measur
vaccin
efficaci
strain
depend
use
mice
lack
abil
respond
type
interferon
highli
suscept
lethal
chikv
infect
mice
use
success
test
chikv
vaccin
sinc
vaccin
fail
produc
potent
antibodi
respons
fail
protect
chikv
challeng
chikvvaccin
mice
protect
model
even
high
challeng
dose
highlight
robust
singledos
vaccin
furthermor
high
titer
viremia
produc
chikv
infect
mice
chikv
vaccin
abl
reduc
challeng
viremia
level
undetect
level
day
highest
anticip
titer
featur
critic
arboviru
vaccin
decreas
potenti
mosquito
transmiss
despit
use
evalu
safeti
efficaci
mice
also
show
mortal
follow
chikv
observ
chikvinfect
patient
mice
often
use
vaccin
studi
sinc
fullyintact
type
interferon
respons
show
foot
swell
succumb
chikv
infect
given
chik
vaccin
describ
safe
effect
character
includ
dose
longterm
immunogen
studi
mice
warrant
vector
vaccin
describ
design
express
multilineag
mosaic
protein
aim
widen
protect
chikv
lineag
hypothes
neutral
antibodi
chikv
surfac
antigen
correl
protect
capsid
intern
structur
protein
might
less
requir
induc
effect
immun
test
design
altern
vaccin
chikv
structur
cassett
lack
capsid
gene
signific
differ
surviv
viremia
weight
loss
chikand
chik
mice
follow
lethal
chikv
challeng
condit
test
nevertheless
awar
differ
protect
may
emerg
condit
chang
reduct
vaccin
dose
assess
longterm
efficaci
afford
presenc
absenc
capsid
part
vaccin
commonli
use
strain
perform
vivo
vaccin
efficaci
studi
lr
strain
howev
multipl
lineag
chikv
found
worldwid
slightli
differ
phenotyp
mous
regardless
known
chikv
compris
one
serotyp
antibodi
immun
one
lineag
crossneutr
anoth
prechalleng
serum
test
prnt
lr
strain
futur
studi
expand
upon
panel
confirm
highneutr
antibodi
titer
known
lineag
add
evid
cross
protect
efficaci
mosaic
antigen
evalu
chikf
becom
major
global
health
concern
due
abil
caus
debilit
longterm
joint
pain
arthriti
infect
individu
recent
scientif
effort
result
promis
chikv
candid
vaccin
go
preclin
phase
ii
clinic
trial
howev
vaccin
yet
licens
multipl
vaccin
develop
use
wide
varieti
approach
includ
liveattenu
protein
subunit
viralvector
nucleic
acidderiv
approach
benefit
drawback
chimpanze
adenovirusvector
approach
use
combin
enhanc
safeti
profil
par
inactiv
vaccin
evidenc
signific
weight
loss
mice
directli
follow
vaccin
immunogen
compar
liveattenu
vaccin
shown
lack
viremia
swell
well
surviv
lethal
challeng
believ
vaccin
show
great
promis
evalu
nonhuman
primat
clinic
trial
vero
cell
american
type
cultur
collect
manassa
va
usa
maintain
dulbecco
minim
essenti
media
dmem
gibco
thermofish
scientifc
waltham
usa
supplement
fetal
bovin
serum
fb
atlanta
biolog
floweri
branch
ga
usa
penicillinampicillin
gibco
thermofish
scientif
waltham
usa
cell
cultur
maintain
incub
set
c
co
viralvector
vaccin
construct
univers
oxford
consist
chimpanze
adenovir
vector
platform
delet
locu
respons
viral
replic
gene
genet
cassett
design
base
structur
sequenc
chikv
insert
earli
gene
delet
vector
use
gateway
cassett
invitrogen
degre
conserv
analyz
consensu
sequenc
three
chikv
lineag
util
design
synthet
gene
construct
two
vaccin
one
whole
structur
cassett
chik
one
without
capsid
chik
chik
contain
fulllength
polyprotein
chikv
includ
capsid
envelop
e
plasmid
use
dna
templat
gener
cassett
delet
capsid
chik
pcr
clone
transgen
clone
pmono
plasmid
control
cmv
promot
detail
describ
zika
zika
prme
use
neg
control
presenc
insert
cassett
vector
confirm
pcr
sequenc
viru
purifi
cesium
chlorid
cscl
gradient
ultracentrifug
assess
steril
result
product
titrat
obtain
infecti
unit
iu
per
ml
assay
spectrophotometri
measur
number
viru
particl
vp
per
ml
chik
titer
iuml
ratio
vp
iu
chik
titer
iuml
ratio
vp
iu
zika
titer
iuml
ratio
vp
iu
vaccin
excipi
made
tri
sucros
nacl
ph
chik
chik
zika
manufactur
viral
vector
core
facil
jenner
institut
univers
oxford
chikv
vaccin
rescu
cdna
clone
describ
vaccin
develop
unit
state
armi
medic
research
institut
infecti
diseas
usamriid
passag
southeast
asian
human
isol
cell
time
stock
titrat
tissu
cultur
media
list
frozen
c
readi
use
cdna
clone
encod
lr
strain
chikv
use
rescu
viru
use
challeng
inform
regard
cdna
construct
rescu
report
mice
typei
interferon
receptordefici
mice
genet
background
maintain
steril
cage
breed
coloni
utmb
mice
gender
random
cohort
vaccin
time
individu
mice
earnotch
identifi
anim
manipul
done
accord
approv
institut
anim
care
use
iacuc
protocol
utmb
aalasapprov
facil
mous
reach
human
endpoint
euthan
co
asphyxi
includ
paralysi
tremor
inabl
move
stimul
inabl
eatdrink
greater
weight
loss
day
death
record
day
euthanasia
immedi
prior
vaccin
vaccin
thaw
ice
thaw
c
vaccin
dilut
dulbecco
phosphat
buffer
salin
dpb
gibco
thermofish
scientif
waltham
usa
room
temperatur
transport
anim
facil
vaccin
vaccin
except
ship
frozen
readytodilut
formul
vaccin
dilut
deliv
dose
iu
per
mous
back
titrat
vaccin
vaccin
titrat
directli
vaccin
determin
pfuml
pfumous
vaccin
given
intramuscularli
hind
leg
leg
isofluraneanesthet
mous
thirti
day
post
vaccin
mice
anesthet
isofluran
chikvlr
inject
intraderm
left
foot
toward
ankl
portion
contact
ground
use
g
insulin
syring
volum
right
foot
inject
back
titrat
viru
yield
dose
pfumous
mice
weigh
daili
weight
compar
weight
day
challeng
mous
lost
initi
weight
human
euthan
death
record
day
euthanasia
swell
measur
previous
describ
foot
thick
measur
feet
ensur
measur
consist
effort
made
reduc
pain
stress
foot
inject
includ
limit
challeng
one
foot
provid
soft
bed
nest
materi
mice
durat
challeng
phase
day
post
challeng
mice
anesthet
isofluran
blood
collect
retroorbit
sinu
capillari
tube
twentyon
day
post
challeng
remain
mice
euthan
day
post
vaccin
day
post
challeng
mice
anesthet
isofluran
blood
collect
retroorbit
immedi
euthanasia
mice
exsanguin
intracardiac
bleed
blood
spun
microfug
tube
g
min
serum
remov
place
new
tube
sampl
frozen
c
viru
sera
titrat
perform
vero
cell
monolay
plate
describ
previous
briefli
sampl
underw
serial
dilut
media
use
infect
confluent
vero
cell
monolay
semisolid
overlay
contain
agaros
ad
allow
solidifi
plate
incub
c
co
approxim
h
fixat
formaldehyd
solut
monolay
stain
crystal
violet
visual
plaqu
data
repres
pfuml
assay
limit
detect
lod
pfuml
valu
less
lod
record
lod
statist
graph
purpos
valu
assum
pfuml
ie
half
lod
prnt
assay
perform
chikvlr
previous
describ
sera
heatinactiv
c
h
dilut
media
initi
dilut
known
amount
viru
incub
serum
dilut
h
virusserum
dilut
use
infect
vero
cell
monolay
plate
plate
treat
like
viru
titrat
point
number
plaqu
unneutr
well
make
reduct
prnt
yield
plaqu
reduct
prnt
yield
plaqu
lod
titer
titer
set
half
lod
titer
viremia
data
transform
log
pfuml
prior
analysi
surviv
curv
comparison
made
use
prism
softwar
logrank
mantelcox
test
prnt
data
analyz
reciproc
titer
use
oneway
anova
dunnett
multipl
comparison
test
n
number
suffici
normal
assess
dagostino
pearson
kolmogorovsmirnov
test
multipl
pair
twotail
ttest
oneway
twoway
anova
correct
multipl
comparison
test
use
appropri
dunnett
test
use
compar
control
pb
group
sidak
compar
select
pair
case
data
repres
mean
individu
valu
standard
error
mean
sem
signific
differ
consid
adjust
pvalu
analys
done
use
prism
graphpad
